Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nuance Acquires Rights to Novel COPD Therapy From Verona in $219 Million Deal

publication date: Jun 10, 2021

Shanghai Nuance Pharma acquired greater China rights to a novel COPD treatment from Verona Pharma of London in a $219 million deal. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, offering both bronchodilator and anti-inflammatory effects. Verona is currently testing ensifentrine in a global Phase III trial as a maintenance treatment for chronic obstructive pulmonary disease. Nuance will make a $25 million upfront payment and a $15 million investment in Verona, plus milestones of up to $179 million and royalties. More details....

Stock Symbol: (NSDQ: VRNA)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here